Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Product Surveillance, Postmarketing | 19 | 2021 | 430 | 2.990 |
Why?
|
Adverse Drug Reaction Reporting Systems | 11 | 2018 | 469 | 1.700 |
Why?
|
United States Food and Drug Administration | 16 | 2022 | 1584 | 1.500 |
Why?
|
Computer Communication Networks | 7 | 2020 | 295 | 1.500 |
Why?
|
Comparative Effectiveness Research | 4 | 2019 | 681 | 1.360 |
Why?
|
Electronic Health Records | 18 | 2021 | 4468 | 1.200 |
Why?
|
Databases, Factual | 21 | 2022 | 7730 | 0.940 |
Why?
|
Sentinel Surveillance | 5 | 2018 | 281 | 0.910 |
Why?
|
Fructose | 3 | 2006 | 289 | 0.720 |
Why?
|
Multicenter Studies as Topic | 2 | 2013 | 1677 | 0.640 |
Why?
|
Influenza Vaccines | 3 | 2009 | 738 | 0.610 |
Why?
|
International Classification of Diseases | 2 | 2022 | 867 | 0.560 |
Why?
|
Insurance Claim Review | 5 | 2022 | 720 | 0.510 |
Why?
|
Migraine Disorders | 4 | 2008 | 1620 | 0.490 |
Why?
|
Clinical Laboratory Information Systems | 1 | 2014 | 108 | 0.440 |
Why?
|
Drug Utilization Review | 2 | 2010 | 245 | 0.400 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 186 | 0.400 |
Why?
|
Research Design | 8 | 2019 | 5986 | 0.380 |
Why?
|
Valproic Acid | 1 | 2013 | 445 | 0.360 |
Why?
|
Health Maintenance Organizations | 7 | 2013 | 642 | 0.360 |
Why?
|
Neuroprotective Agents | 2 | 2006 | 941 | 0.360 |
Why?
|
Population Surveillance | 3 | 2009 | 2616 | 0.340 |
Why?
|
United States | 37 | 2022 | 69869 | 0.330 |
Why?
|
Medical Records Systems, Computerized | 3 | 2009 | 1205 | 0.320 |
Why?
|
Health Planning | 2 | 2014 | 238 | 0.320 |
Why?
|
Urticaria | 1 | 2009 | 150 | 0.320 |
Why?
|
Antifungal Agents | 1 | 2013 | 729 | 0.320 |
Why?
|
Drugs, Generic | 1 | 2013 | 421 | 0.310 |
Why?
|
Information Systems | 1 | 2010 | 410 | 0.310 |
Why?
|
Data Mining | 1 | 2013 | 537 | 0.310 |
Why?
|
Data Collection | 4 | 2020 | 3339 | 0.310 |
Why?
|
Health Care Reform | 1 | 2016 | 1261 | 0.290 |
Why?
|
Insurance, Health | 3 | 2021 | 2494 | 0.290 |
Why?
|
Pharmacoepidemiology | 3 | 2016 | 323 | 0.280 |
Why?
|
Models, Econometric | 1 | 2005 | 218 | 0.250 |
Why?
|
Insurance Coverage | 1 | 2016 | 1900 | 0.250 |
Why?
|
Anti-Asthmatic Agents | 2 | 2021 | 536 | 0.250 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1438 | 0.230 |
Why?
|
Anticonvulsants | 1 | 2013 | 1916 | 0.220 |
Why?
|
Pharmaceutical Preparations | 2 | 2022 | 1070 | 0.220 |
Why?
|
Models, Statistical | 5 | 2014 | 5101 | 0.220 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3020 | 0.210 |
Why?
|
Models, Economic | 1 | 2006 | 712 | 0.210 |
Why?
|
Health Status Indicators | 1 | 2008 | 970 | 0.210 |
Why?
|
Software | 4 | 2014 | 4442 | 0.200 |
Why?
|
Clinical Coding | 2 | 2021 | 171 | 0.200 |
Why?
|
Health Services Research | 1 | 2009 | 1836 | 0.200 |
Why?
|
Pilot Projects | 6 | 2021 | 8319 | 0.200 |
Why?
|
Hypoglycemic Agents | 1 | 2013 | 2873 | 0.190 |
Why?
|
Meningococcal Vaccines | 3 | 2012 | 95 | 0.180 |
Why?
|
Humans | 62 | 2022 | 744376 | 0.170 |
Why?
|
Guillain-Barre Syndrome | 2 | 2012 | 120 | 0.170 |
Why?
|
Disease Outbreaks | 1 | 2008 | 1771 | 0.170 |
Why?
|
Biological Products | 3 | 2021 | 860 | 0.170 |
Why?
|
Computer Simulation | 2 | 2014 | 6194 | 0.170 |
Why?
|
Competitive Medical Plans | 2 | 2009 | 24 | 0.160 |
Why?
|
Drug Approval | 3 | 2011 | 742 | 0.160 |
Why?
|
Arthroplasty, Replacement | 1 | 2022 | 339 | 0.160 |
Why?
|
Drug Utilization | 3 | 2021 | 1183 | 0.160 |
Why?
|
Legislation, Drug | 2 | 2004 | 206 | 0.160 |
Why?
|
Algorithms | 7 | 2022 | 13882 | 0.160 |
Why?
|
Time Factors | 11 | 2018 | 40077 | 0.160 |
Why?
|
Internet | 1 | 2010 | 3064 | 0.150 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1856 | 0.150 |
Why?
|
Influenza, Human | 1 | 2008 | 1479 | 0.150 |
Why?
|
Computer Security | 3 | 2014 | 262 | 0.150 |
Why?
|
Technology | 1 | 2019 | 305 | 0.150 |
Why?
|
Lyme Disease | 1 | 2022 | 621 | 0.140 |
Why?
|
Drug Labeling | 1 | 2018 | 233 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 346 | 0.130 |
Why?
|
Quality of Health Care | 1 | 2010 | 4369 | 0.120 |
Why?
|
Osteoarthritis | 1 | 2022 | 1036 | 0.120 |
Why?
|
Natural Language Processing | 2 | 2019 | 1041 | 0.120 |
Why?
|
Feasibility Studies | 3 | 2016 | 5077 | 0.120 |
Why?
|
Risk | 5 | 2014 | 9688 | 0.120 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2019 | 2020 | 0.120 |
Why?
|
Orphan Drug Production | 1 | 2014 | 50 | 0.120 |
Why?
|
Information Storage and Retrieval | 1 | 2019 | 824 | 0.120 |
Why?
|
Medical Records | 1 | 2019 | 1413 | 0.120 |
Why?
|
Public Health Informatics | 1 | 2014 | 110 | 0.120 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 941 | 0.110 |
Why?
|
Adult | 22 | 2022 | 214056 | 0.110 |
Why?
|
Proton Pump Inhibitors | 1 | 2018 | 526 | 0.110 |
Why?
|
Antibodies | 1 | 2021 | 2460 | 0.110 |
Why?
|
Equipment and Supplies | 2 | 2012 | 281 | 0.110 |
Why?
|
Adolescent | 12 | 2021 | 85784 | 0.110 |
Why?
|
Confidentiality | 2 | 2014 | 612 | 0.100 |
Why?
|
Databases as Topic | 1 | 2014 | 475 | 0.100 |
Why?
|
Likelihood Functions | 2 | 2013 | 1005 | 0.100 |
Why?
|
Biomedical Research | 3 | 2020 | 3309 | 0.100 |
Why?
|
Epidemiologic Research Design | 2 | 2014 | 367 | 0.100 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 312 | 0.100 |
Why?
|
Quinoxalines | 1 | 2013 | 290 | 0.100 |
Why?
|
Bupropion | 1 | 2013 | 303 | 0.100 |
Why?
|
Nicotinic Agonists | 1 | 2013 | 271 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1790 | 0.100 |
Why?
|
Benzazepines | 1 | 2013 | 326 | 0.100 |
Why?
|
Middle Aged | 18 | 2021 | 213388 | 0.100 |
Why?
|
Asthma | 2 | 2021 | 6010 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2011 | 513 | 0.090 |
Why?
|
Software Design | 1 | 2010 | 176 | 0.090 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 387 | 0.090 |
Why?
|
Rare Diseases | 1 | 2014 | 553 | 0.090 |
Why?
|
Cost-Benefit Analysis | 3 | 2006 | 5390 | 0.090 |
Why?
|
Young Adult | 8 | 2021 | 56434 | 0.080 |
Why?
|
Vaccines | 2 | 2014 | 823 | 0.080 |
Why?
|
Benzodiazepines | 2 | 2004 | 1101 | 0.080 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 806 | 0.080 |
Why?
|
Observation | 1 | 2009 | 312 | 0.080 |
Why?
|
Naproxen | 1 | 2007 | 99 | 0.080 |
Why?
|
Drug Prescriptions | 3 | 2013 | 1637 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2019 | 2542 | 0.070 |
Why?
|
Female | 22 | 2021 | 380200 | 0.070 |
Why?
|
Bronchodilator Agents | 1 | 2010 | 502 | 0.070 |
Why?
|
Rhabdomyolysis | 1 | 2007 | 150 | 0.070 |
Why?
|
Propensity Score | 1 | 2013 | 1781 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2200 | 0.070 |
Why?
|
Massachusetts | 2 | 2016 | 8662 | 0.070 |
Why?
|
Child | 8 | 2020 | 77708 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1254 | 0.070 |
Why?
|
Incidence | 2 | 2022 | 20950 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3255 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2016 | 1209 | 0.070 |
Why?
|
Retrospective Studies | 11 | 2022 | 77459 | 0.070 |
Why?
|
Male | 18 | 2021 | 350118 | 0.070 |
Why?
|
Financing, Government | 1 | 2009 | 468 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15221 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1316 | 0.060 |
Why?
|
Lactones | 1 | 2007 | 329 | 0.060 |
Why?
|
Sulfones | 1 | 2007 | 437 | 0.060 |
Why?
|
Economics, Pharmaceutical | 1 | 2005 | 87 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3086 | 0.060 |
Why?
|
Cerebral Ventricles | 1 | 2007 | 544 | 0.060 |
Why?
|
Computer Systems | 2 | 2018 | 483 | 0.060 |
Why?
|
Cerebrospinal Fluid | 1 | 2007 | 535 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2015 | 63115 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2902 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2015 | 15078 | 0.060 |
Why?
|
Aged | 11 | 2021 | 163284 | 0.060 |
Why?
|
Decision Trees | 1 | 2005 | 506 | 0.060 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2008 | 500 | 0.060 |
Why?
|
Decision Support Techniques | 2 | 2019 | 1956 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2008 | 604 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2019 | 15159 | 0.060 |
Why?
|
Child, Preschool | 3 | 2010 | 41005 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7785 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2010 | 1148 | 0.050 |
Why?
|
Cardiovascular Agents | 1 | 2008 | 850 | 0.050 |
Why?
|
Cooperative Behavior | 1 | 2008 | 1504 | 0.050 |
Why?
|
Churg-Strauss Syndrome | 1 | 2021 | 70 | 0.050 |
Why?
|
Anti-Anxiety Agents | 1 | 2004 | 390 | 0.050 |
Why?
|
Smoking Cessation | 1 | 2013 | 2071 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3339 | 0.050 |
Why?
|
Administration, Inhalation | 2 | 2016 | 1105 | 0.050 |
Why?
|
Fractures, Bone | 1 | 2013 | 1947 | 0.050 |
Why?
|
Occupational Health Services | 1 | 2002 | 154 | 0.050 |
Why?
|
Medicaid | 2 | 2004 | 2737 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2006 | 1683 | 0.050 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 968 | 0.050 |
Why?
|
Vaccination | 1 | 2012 | 3279 | 0.040 |
Why?
|
Logistic Models | 2 | 2013 | 13409 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2012 | 3589 | 0.040 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 297 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3610 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8091 | 0.040 |
Why?
|
Cohort Studies | 6 | 2022 | 40558 | 0.040 |
Why?
|
Pneumonia | 1 | 2010 | 2133 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2047 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 1995 | 5135 | 0.040 |
Why?
|
Sulfonamides | 1 | 2007 | 1940 | 0.040 |
Why?
|
Infant | 2 | 2010 | 35134 | 0.040 |
Why?
|
Pyrazoles | 1 | 2007 | 1972 | 0.040 |
Why?
|
Consumer Product Safety | 1 | 2018 | 122 | 0.040 |
Why?
|
Program Evaluation | 3 | 2018 | 2488 | 0.040 |
Why?
|
Pregnant Women | 1 | 2021 | 568 | 0.030 |
Why?
|
Quality of Life | 2 | 2008 | 12803 | 0.030 |
Why?
|
Pyridines | 1 | 2007 | 2825 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 11725 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 3047 | 0.030 |
Why?
|
Investigational New Drug Application | 1 | 1995 | 6 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3395 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2007 | 2838 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2019 | 780 | 0.030 |
Why?
|
Health Education | 1 | 2002 | 1056 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 764 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3658 | 0.030 |
Why?
|
Decision Making | 1 | 2008 | 3888 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2007 | 3748 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2007 | 3326 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2007 | 4042 | 0.030 |
Why?
|
New Jersey | 2 | 2004 | 290 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2016 | 6489 | 0.030 |
Why?
|
Risk Assessment | 2 | 2013 | 23336 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7658 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2007 | 2861 | 0.030 |
Why?
|
Drug Evaluation | 1 | 1995 | 647 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2004 | 1622 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2018 | 401 | 0.030 |
Why?
|
Drugs, Investigational | 1 | 1995 | 214 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2282 | 0.030 |
Why?
|
Drug Therapy | 1 | 1995 | 497 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 1995 | 13695 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2021 | 3773 | 0.030 |
Why?
|
Prospective Studies | 3 | 2013 | 53291 | 0.030 |
Why?
|
Privacy | 1 | 2014 | 238 | 0.030 |
Why?
|
Validation Studies as Topic | 1 | 2011 | 159 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2019 | 20823 | 0.020 |
Why?
|
New York | 2 | 2004 | 886 | 0.020 |
Why?
|
Japan | 1 | 1995 | 1360 | 0.020 |
Why?
|
Sample Size | 1 | 2014 | 845 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2971 | 0.020 |
Why?
|
Vaccines, Conjugate | 1 | 2012 | 333 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.020 |
Why?
|
Health Promotion | 1 | 2002 | 2205 | 0.020 |
Why?
|
Case-Control Studies | 4 | 2010 | 21747 | 0.020 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2014 | 373 | 0.020 |
Why?
|
Albuterol | 1 | 2010 | 208 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 4424 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2005 | 9957 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2661 | 0.020 |
Why?
|
Androstadienes | 1 | 2010 | 345 | 0.020 |
Why?
|
Osteoporosis | 1 | 2018 | 1579 | 0.020 |
Why?
|
Pregnancy | 3 | 2021 | 29144 | 0.020 |
Why?
|
Teratogens | 1 | 2008 | 112 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2004 | 4257 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2013 | 688 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2002 | 3922 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2007 | 288 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2008 | 25041 | 0.020 |
Why?
|
History, 20th Century | 1 | 1995 | 2740 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2012 | 1364 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2007 | 11718 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3677 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14723 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3519 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.020 |
Why?
|
Documentation | 1 | 2011 | 871 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1405 | 0.020 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 451 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3468 | 0.020 |
Why?
|
Risk Factors | 4 | 2018 | 72295 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5321 | 0.020 |
Why?
|
Mental Disorders | 1 | 2004 | 6600 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 1516 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8386 | 0.010 |
Why?
|
Brain | 1 | 2007 | 26386 | 0.010 |
Why?
|
Outpatients | 1 | 2008 | 1487 | 0.010 |
Why?
|
Prenatal Care | 1 | 2007 | 1092 | 0.010 |
Why?
|
Prenatal Diagnosis | 1 | 2007 | 1236 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 35424 | 0.010 |
Why?
|
Self Efficacy | 1 | 2002 | 616 | 0.010 |
Why?
|
Awareness | 1 | 2002 | 640 | 0.010 |
Why?
|
Odds Ratio | 1 | 2010 | 9849 | 0.010 |
Why?
|
American Heart Association | 1 | 2002 | 1057 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39052 | 0.010 |
Why?
|
Probability | 1 | 2002 | 2506 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3508 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 57776 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4982 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 13988 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2004 | 2265 | 0.010 |
Why?
|
Age Factors | 1 | 2010 | 18373 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15535 | 0.010 |
Why?
|
Health Behavior | 1 | 2002 | 2635 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2007 | 19905 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2007 | 25628 | 0.000 |
Why?
|